University Hospital, Angers

chu-angers.fr

Total trials

464

Active

109

Phase 3

32

Total enrollment

504,631

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 20 of 20 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Cyclosporine2
Nicotinamide1
Idarubicin1
Daunorubicin1
HD Cytarabine1
Methotrexate1
Mycophenolic acid1
vosaroxin1
ID cytarabine1
Dexamethasone1
Venetoclax1
Rivaroxaban 10 MG1
Low Heparin Molecular Weight1
Nicotinamide treatment1
Whole blood samples1
Clonal architecture determination1
Blood test1
Sulthiame1
CALR allele burden quantification1
Continuous measurement of uPO21

Next readouts

  • 2025-07
  • 2025-12-01
  • 2026-07-09
  • 2026-09
  • 2026-11-19
  • 2027-04-23
  • 2027-04-28
  • 2027-09-01
  • 2027-10-18
  • 2028-04

Top conditions

  • Peripheral Artery Disease11
  • Pseudoxanthoma Elasticum9
  • Pulmonary Embolism8
  • Septic Shock7
  • Peripheral Arterial Disease7
  • Thoracic Outlet Syndrome6
  • Healthy6
  • Anesthesia5

Frequently asked questions about University Hospital, Angers

How many clinical trials does University Hospital, Angers have on ClinicalTrials.gov?
University Hospital, Angers is listed as the lead sponsor on 464 clinical trials in ClinicalTrials.gov, 109 of which are currently active (recruiting, enrolling, or ongoing).
How many of University Hospital, Angers's trials are in Phase 3?
32 of University Hospital, Angers's trials are in Phase 3, spread across 20 active drug programs.
What therapeutic areas does University Hospital, Angers focus on?
University Hospital, Angers's most-studied conditions on ClinicalTrials.gov are Peripheral Artery Disease, Pseudoxanthoma Elasticum, Pulmonary Embolism, Septic Shock, Peripheral Arterial Disease.
When are University Hospital, Angers's next clinical trial readouts?
University Hospital, Angers has 10 upcoming primary-completion readouts tracked here; the soonest is “Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR”, expected around 2025-07.